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A b s t r a c t
Background: The effects of pre-existing anaemia on the occurrence and course of an acute coronary syndrome has recently
become a topic of extensive research. The data on the significance of anaemia in patients with ST-elevation myocardial
infarction (STEMI) undergoing percutaneous coronary intervention (PCI) are less abundant and the conclusions equivocal.
Aim: To evaluate the incidence of anaemia and its impact on early outcomes in patients undergoing primary PCI for STEMI.
Methods: Based on a retrospective review of the medical records of hospitalised patients we selected a study group compri-
sing 551 consecutive patients with STEMI, including 164 females, mean age 63.4 ± 12 years, undergoing primary PCI within
the first 12 hours after the onset of chest pain. Anaemia was diagnosed according to the World Health Organisation criteria
based on haemoglobin (Hb) values on admission (< 12 g/dL for females, < 13 g/dL for males).
Results: Anaemia was diagnosed in 61 (11%) patients (in 13% of females and 10% of males). The anaemic patients were older
(71 vs 63 years, p < 0.001), had a lower body mass (70 vs 80 kg, p < 0.003) and a higher TIMI risk score for STEMI (5 vs 3,
p < 0.0001). Their laboratory results showed a greater renal impairment (GFR 66.8 vs 75.8 mL/min, p < 0.008) and higher
C-reactive protein levels (24.8 vs 14.4 mg/L, p < 0.001). There were no significant differences in post-infarction myocardial
damage as estimated on the basis of ejection fraction and the baseline and peak CK-MB levels. During treatment, in both
groups, there was a significant decrease in Hb levels from 11.9 to 11.0 g/dL in the anaemic patients (p < 0.0004) and from 14.3
to 13.3 g/dL in the non-anaemic patients (p < 0.001). While GFR did not change significantly in the anaemic patients, there was
a significant increase in the non-anaemic patients from 75.8 to 80.9 mL/min (p < 0.001). The in-hospital mortality was low with
a total of 8 (1.3%) patients dying: 5 (8.2%) in the anaemic group and 3 (0.6%) in the non-anaemic group (p < 0.001). The
anaemic patients were also characterised by a higher incidence of cardiovascular complications (33% vs 17%, p = 0.003). In the
multivariate analysis, older age, systolic blood pressure on admission and elevated white blood count were independently
associated with a higher risk of death and cardiovascular complications, whereas baseline Hb level was a significant prognostic
factor only in the univariate analysis.
Conclusions: Patients with anaemia who develop STEMI are, right from the admission, a separate, higher-risk population of
patients with considerably increased risk of death and in-hospital cardiovascular complications. The unfavourable impact of
anaemia on outcomes in patients with acute MI undergoing PCI is complex and cannot be explained by the increased extend of
post-infarction myocardial damage. In patients with STEMI, anaemia on admission should be treated as an additional risk factor.
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INTRODUCTION
According to various sources, anaemia is present in 15–30%
of patients with acute coronary syndrome (ACS) and became
a topic of extensive research only a few years ago. As in heart
failure (HF), anaemia adversely affects the outcomes of ACS
[1–3]. The significance of anaemia in ACS, particularly in the
era of widespread percutaneous coronary interventions (PCI)
and an increasingly effective antiplatelet treatment, has gene-
rated interest among many researchers in the past decade [4,
5]. The majority of publications addressing anaemia in ACS
have focussed on the significance of haemorrhagic complica-
tions during the treatment of myocardial infarction (MI) and
on the prognostic significance of transfusions [6–8]. Less at-
tention has been devoted to the significance of anaemia di-
scovered upon the diagnosis of ACS.
The aim of the study was to evaluate the incidence of
anaemia diagnosed on admission and its impact on outco-
mes in patients undergoing PCI for ST-elevation MI (STEMI).
METHODS
This was a retrospective analysis of medical records of pa-
tients hospitalised in our department between May and De-
cember 2005. We included consecutive patients with the
diagnosis of STEMI who underwent PCI (primary percutane-
ous transluminal coronary angioplasty [PTCA] with or witho-
ut stenting) within 12 hours after the onset of chest pain.
The diagnosis of STEMI was made on the basis of the
typical clinical presentation, an ST elevation on ECG of more
than 20 minutes’ duration (in two adjacent leads, > 0.2 mV
for precordial leads and > 0.1 mV for the remaining leads)
and elevated levels of myocardial injury markers (the creati-
nine kinase MB fraction [CK-MB]).
Patients underwent PCI right after admission, using fe-
moral approach and in accordance with the commonly re-
cognised standards (using standard 6 F Judkins catheters).
Anaemia was identified based on full blood count results on
admission, in accordance with the World Health Organisa-
tion  definition (haemoglobin [Hb] < 12 g/dL in females and
< 13 g/dL in males) [9]. The group of anaemic patients was
compared with that of non-anaemic patients in terms of de-
mographic, clinical and laboratory parameters.
Analysed parameters
We analysed: demographic parameters: age, sex, body mass;
historical data: current and past illnesses, duration and se-
verity of coronary artery disease, smoking status; hospitali-
sation-related data: infarct location, duration of the chest
pain before admission, blood pressure and haemodynamic
status on admission according to Killip’s classification, TIMI
risk score for STEMI (developed by Morrow and Antman),
duration of hospitalisation at the Intensive Coronary Care
Unit (ICCU); deaths and in-hospital cardiovascular (CV) com-
plications (cardiac arrest, shock, myocardial rupture, pul-
monary oedema, life-threatening cardiac arrhythmias and
conduction disorders); ejection fraction (EF) assessed by
echocardiography using the visual method within the first
24 hours after admission; laboratory parameters (full blood
counts on admission and the lowest Hb level during the
entire hospitalisation, the myocardial injury marker CK-MB,
C-reactive protein [CRP], and the baseline and lowest glo-
merular filtration rate [GFR] values calculated from the Cock-
croft-Gault formula).
Statistical analysis
Quantitative variables with a normal distribution are presen-
ted as mean and SD, and quantitative variables without
a normal distribution — as median, quartiles, maximum and
minimum. The normality of the distribution was verified with
the Kolmogorov-Smirnov and Lilliefors test for normality. We
used the c2 test of independence to check the relationship
between the qualitative variables. We compared ordinal va-
riables using the non-parametric U Mann-Whitney test in the
case of two groups and the non-parametric Kruskal-Wallis
ANOVA rank test with a post-hoc multiple comparison mean
rank test for all the samples in the case of multiple groups.
We also determined a Spearman’s rank order correlation co-
efficient. We carried out univariate logistic regression for the
analysed features and determined the multiple logistic regres-
sion model. Statistically significant results were at the p value
of < 0.05. We used Statistica 8.0 (StatSoft) for our calcula-
tions.
RESULTS
A total of 551 patients with the diagnosis of STEMI who un-
derwent primary PCI within the first 12 hours after the onset
of chest pain were included in the study (mean age 63.4 ±
± 12 years, 164 women [30% of the analysed population]).
These were patients with multiple risk factors: overweight
(median BMI 28 kg/m2), more than a half of the patients (52%)
had hypertension, 16% had diabetes mellitus, 12% had a hi-
story of MI and 7% had a history of stroke. Nearly half (42%)
of the patients were smokers.
Based on the Hb levels on admission we identified
a group of 61 (11%) patients with anaemia, 22 women and
39 men. Most patients had mild anaemia. Haemoglobin was
below 10 g/dL in only 1 (1.6%) patient, 10.9–11.9 g/dL in
31 (50.8%) patients, and 12.0–13.0 g/dL in the remaining
29 (47.6%) patients. Based on a retrospective analysis of the
medical records the cause of anaemia on admission could
be established in only 32 patients. In 26 patients it was ana-
emia of chronic disease (mainly gastrointestinal disease, chro-
nic kidney disease and locomotor system disorders) and in
6 patients it was iron deficiency anaemia. In the remaining
29 patients, based on the analysis of full blood cell counts,
we established the presence of normocytic anaemia at un-
known origin.
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Compared to the non-anaemic patients, patients with
anaemia were significantly older and had a lower body mass.
We found no significant differences between the groups with
regard to demographic and medical history parameters (Ta-
ble 1). The groups did not differ in terms of infarct location,
duration of chest pain or the EF on admission. The anaemic
patients on admission had a significantly lower blood pressu-
re, both systolic and diastolic, and a significantly higher heart
rate. In terms of the baseline cardiac function they were in
the higher Killip-Kimball class (Table 2). In order to assess and
compare the risk in both groups we used the TIMI risk score
for STEMI. The anaemic patients had significantly higher sco-
res suggestive of a significantly higher risk for this group. This
fact was indirectly reflected by the duration of hospitalisation
at the ICCU, which was nearly one day longer in the case of
the patients with anaemia.
Tables 3 and 4 compare the laboratory parameters be-
tween both groups. We observed a significant decrease in Hb
in both groups during hospitalisation. We found no differen-
ces between the groups in CK-MB activity on admission or
between peak values (Table 3). Baseline CRP was considera-
bly elevated both in the anaemic and non-anaemic patients
and was significantly higher in the anaemic group. In both
groups the GFR suggested mild renal impairment (class I ac-
cording to the Polish Nephrologic Society). In the anaemic
patients, however, it was significantly lower than that in the
patients without anaemia (Table 4). We found a positive corre-
lation between Hb on admission and baseline GFR (r = 0.18,
Table 2. A comparison of the markers of clinical and haemodynamic status in patients with and without anaemia
Parameter Non-anaemic patients (n = 490) Anaemic patients (n = 61) P
Myocardial infarction location:
Anterior 197 (40%) 27 (44%) NS
Inferior 274 (56%) 30 (49%) NS
Other 17 (4%) 4 (7%) NS
Duration of chest pain before admission [min]* 240 (180–360) 240 (180–450) NS
SBP on admission [mm Hg]* 135 (120–150) 125 (105–150) 0.01
DBP on admission [mm Hg]* 80 (80–100) 80 (70–90) 0.02
HR on admission [bpm]* 75 (64–90) 80 (67–100) 0.04
TIMI score (for STEMI)* 3 (2–5) 5 (3–7) 0.00001
Killip class* 2 (2–2) 2 (2–3) < 0.002
Ejection fraction [%]* 48 (38–52) 46 (38–50) NS
Duration of hospitalisation at ICCU [days]* 2 (2–3) 3 (2–4) 0.009
*Median values with the lower and upper quartiles given in parentheses; SBP — systolic blood pressure; DBP — diastolic blood pressure; HR — heart
rate; TIMI — Thrombolysis In Myocardial Infarction; STEMI — ST-elevation myocardial infarction; ICCU — Intensive Coronary Care Unit
Table 1. Demographic and clinical parameters in patients with and without anaemia
Parameter Non-anaemic patients (n = 490) Anaemic patients (n = 61) P
Age [years]* 63.0 (53–72) 71.0 (63–76) 0.0006
Sex: female/male 142 (29%)/348 (71%) 22 (36%)/39 (64%) NS
Body mass [kg]* 80 (70–88) 70 (61–82) 0.003
BMI [kg/m2]* 27.6 (24.9–30.3) 25.5 (22.2–31.3) NS
History of MI 56 (11%) 10 (16%) NS
History of PCI 25 (5.0%) 4 (6.5%) NS
History of CABG 9 (2%) 0 NS
History of stroke 34 (7%) 3 (5%) NS
Hypertension 250 (51%) 38 (62%) NS
Diabetes mellitus 75 (15%) 12 (20%) NS
Smoking 213 (43%) 18 (30%) NS
*Median values with the lower and upper quartiles given in parentheses; BMI — body mass index; MI — myocardial infarction; PCI — percutaneous
coronary intervention; CABG — coronary artery bypass grafting
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p < 0.00001) and the lowest GFR (r = 0.2, p < 0.00001).
We also observed that GFR in the non-anaemic patients du-
ring hospitalisation significantly increased, while the change
in the anaemic patients was non-significant.
We analysed deaths and in-hospital complications. A total
of 8 (1.3%) patients died in the study (5 [8.2%] and 3 [0.6%]
in the anaemic and non-anaemic groups, respectively, p =
= 0.001). The rate of CV complications was twice as high in the
anaemic vs non-anaemic patients (33% vs 17%, p = 0.003).
Uni- and multivariate analysis was used to evaluate the im-
pact of the individual factors on mortality and CV complica-
tions (Tables 5, 6). In the univariate analysis (Table 5), the
Table 3. A comparison of haematologic parameters on admission and the lowest values during hospitalisation between the
patients with and without anaemia
Parameter Non-anaemic patients (n = 490) Anaemic patients (n = 61) P
Hb on admission [g/dL] 14.3 (13.6–15.2) 11.9 (11.3–12.6) 0.00001
Lowest Hb value during hospitalisation [g/dL] 13.3 (12.4–14.2) 11.0 (10.3–12.1) 0.00001
WBC on admission [thousand/mL] 11.4 (9.3–13.6) 9.8 (8.6–11.4) 0.0008
Lowest WBC value during hospitalisation [thousand/mL] 216.5 (182.0–266.5) 208.0 (180.0–265.0) NS
Hb — haemoglobin; WBC — white blood count
Table 4. A comparison of myocardial injury markers, inflammation markers and renal function markers in patients with and without
anaemia
Parameter Non-anaemic patients (n = 490) Anaemic patients (n = 61) P
CK-MB on admission [IU/L] 37.0 (25.0–72.5) 36.0 (23.0–74.0) NS
Highest CK-MB value during hospitalisation [IU/L] 185.0 (73.0–325.0) 134.0 (65.0–271.0) NS
C-reactive protein [mg/L] 14.4 (8.0–32.6) 24.8 (15.0–80.2) 0.003
GFR on admission [mL/min] 75.8 (60.9–90.6) 66.8 (44.7–79.2) 0.008
Lowest GFR value during hospitalisation [mL/min] 80.9 (64.1–95.6) 65.8 (38.4–83.9) 0.0006
CK-MB — creatine kinase MB isoenzyme; GFR — glomerular filtration rate
Table 5. Risk factors for death or cardiovascular complications (univariate analysis)
Factor Odds ratio 95% CI P
Age 1.03 1.01–1.05 0.0016
SBP 0.98 0.97–0.99 0.000001
HR 1.01 1.0–1.02 0.046
Ejection fraction 0.95 0.93–0.97 0.00001
Duration of hospitalisation at the ICCU 1.73 1.45–2.05 0.000001
Hb on admission 0.81 0.70–0.94 0.0046
Lowest Hb 0.76 0.66–0.88 0.0003
GFR on admission 0.99 0.98–1.00 0.0046
Lowest GFR 0.98 0.97–0.99 0.00001
CI — confidence interval; Hb — haemoglobin; GFR — glomerular filtration rate; rest abbreviations as in Table 2
Table 6. Risk factors for death or cardiovascular complications (multivariate logistic regression model)
Factor Odds ratio 95% CI P
Age 1.03 1.01–1.05 0.003
Systolic blood pressure 0.98 0.976–0.992 0.0002
Hb on admission 0.89 0.754–1.051 0.17
WBC on admission 1.11 1.046–1.177 0.0006
CI — confidence interval; Hb — haemoglobin; WBC — white blood count
www.kardiologiapolska.pl
37Anaemia in patients with acute STEMI undergoing primary PCI
mortality risk was associated with: age, systolic blood pressu-
re and heart rate on admission, EF, duration of hospitalisation
at the ICCU, Hb on admission and the lowest Hb during tre-
atment, and GFR on admission and the lowest GFR during
treatment. We developed a multivariate logistic regression
model taking into account the following parameters: age,
systolic blood pressure, Hb on admission and white blood
count on admission. The odds ratios and the 95% confiden-
ce intervals for the individual parameters are summarised in
Table 6. Haemoglobin level was not independently associa-
ted with the outcome.
DISCUSSION
By reducing oxygen supply anaemia alone may cause myo-
cardial ischaemia resulting in type 2 MI and may exacerbate
pre-existing myocardial ischaemia and directly lead to ACS.
The decreased supply of oxygen to the myocardium is com-
pensated for by increased cardiac output and blood flow re-
distribution that protects the vital organs [10].
We analysed the significance of anaemia in patients with
STEMI undergoing PCI using a large population of patients
managed at a reference regional facility. In our opinion the
most important finding was that even mild anaemia co-exi-
sting with MI and discovered on admission has an adverse
prognostic significance. Patients with anaemia significantly
differed from the remaining patients in terms of many para-
meters, both demographic, clinical and laboratory ones. Our
findings are consistent with the majority of publications, al-
though some investigators have not confirmed the adverse
influence of reduced Hb on the outcomes in ACS [2, 4, 5, 8].
In contrast to some publications [11, 12], women did not
predominate among the anaemic patients in our study. Some
of our findings cannot be unequivocally explained, such as
the lack of significant differences in the extent of left ventricu-
lar (LV) myocardial injury as assessed by LVEF and CK-MB
levels. This may mean that the adverse influence of anaemia
on the prognosis does not only depend on the extent of myo-
cardial necrosis, but may also result from other unclear fac-
tors, such as chronic inflammation or co-morbidities.
The incidence of anaemia in ACS reported in the litera-
ture ranges from 12% to 30%, which may result from the
selection of the study population [2, 4, 11]. In most publica-
tions all types of ACS were analysed. Perhaps the lower rate
of anaemia in patients with STEMI results from the different
pathomechanism of the infarction (vascular occlusion), other
demographic and clinical features of the population of pa-
tients with STEMI compared to the entire group of patients
with ACS [13–15]. Montalescot et al. [15] compared groups
of patients with STEMI and NSTEMI. The STEMI patients were
younger and predominantly male. They had less co-morbidi-
ties, such as type 2 diabetes mellitus, hypertension, periphe-
ral artery disease. Importantly, there were significantly fewer
patients with a history of HF in the STEMI vs NSTEMI groups
(3.9% vs 8.9%) and this is the most likely reason for the hi-
gher rate of anaemia in patients with non-ST-elevation ACS.
The novelty of our study also rests in the analysis of the
relationship between Hb levels and the TIMI risk score for
STEMI. In patients with ACS, the usefulness of risk scores for
predicting death and CV complications has been proved both
in the short and long term [16, 17]. The score is calculated on
the basis of the following factors: age, body mass, blood pres-
sure and heart rate on admission and the Killip class. It was
significantly higher in the population of anaemic patients.
Few reports on the significance of anaemia in patients with
STEMI undergoing PCI have been published so far [18–20].
The most similar study in terms of demographic and clinical
data to ours is the CADILLAC study [18]. A total of 2000 pa-
tients with acute MI were investigated (with STEMI accounting
for 90% of the cases). The patients underwent primary PTCA
within the first 12 hours after the onset of chest pain. Anaemia
was found in 12.8% of the patients (11% in our study). The
anaemic patients were characterised by higher in-hospital, 30-
-day and 1-year mortality rates. Anaemia was an independent
risk factor for death. Aronson et al. [21] analysed a group of
1390 patients with acute MI (STEMI and NSTEMI) in terms of
the prognostic significance of anaemia. Anaemia was identi-
fied in 17.8% of the patients on admission in and as many as
36.0% at discharge. The lowest Hb was, on average, 1.3 g/dL
lower than the baseline values. This trend was also observed in
our patients, irrespective of their baseline Hb values. The most
likely cause is the blood loss during PCI, especially through the
femoral approach, the aggressive anticoagulant and antiplate-
let treatment and the haemodilution caused by the admini-
stration of intravenous fluids during the first days post-infarc-
tion. The highest prognostic value (higher than anaemia on
admission) had the Hb reduction (a decrease of 1 g/dL in Hb
concentration increased mortality by a factor of 1.36).
In our study population we confirmed the relationship
between anaemia and renal failure. When we compared the
anaemic with non-anaemic patients we found the known
relationship between anaemia and renal failure, also present
in STEMI patients. In a STEMI population similar to ours it was
found that a reduction in Hb levels of 1 g/dL below 15 g/dL
and in creatinine clearance of 10 mL/min was associated with
an increasing mortality risk [12]. As demonstrated by Kruk et
al. [20] in patients with STEMI undergoing primary PCI the
triad of anaemia, hyperglycaemia and elevated serum creati-
nine most adversely affected the outcomes.
Therefore, are the populations of patients with HF and
ACS with co-existent anaemia similar? Or perhaps the adver-
se prognosis in the group of patients with ACS is partially cau-
sed by the co-existent HF? No such comparison has so far
been conducted. Based on the reviewed literature on the re-
lationship between anaemia and HF and based on the com-
parison with our material it seems that anaemia is more pre-
valent in patients with HF than in patients with ACS (up to
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61%) [22]. In both groups we observed a similar increase in
the anaemia rate with age, a relationship with chronic kidney
disease and a poorer prognosis. Due to the retrospective na-
ture of the study we could not establish whether and what
percentage of our patients were carrying the diagnosis of HF
when the infarction was diagnosed. We may only assume,
analysing the co-morbidities, that the proportion of patients
with systolic HF could not have been large (only 12% had
a history of MI). More than a half of the patients had a history
of primary hypertension, which could be associated with pre-
viously undiagnosed HF with preserved EF. The studies con-
ducted in the recent years confirm the relationship between
this form of HF and anaemia both in terms of co-existence
and poor prognosis [23].
It is still unclear whether anaemia is merely a marker of
inflammation or a poor prognostic factor (in the former case
its treatment will not result in any improvement, while in the
latter case treatment will matter) [24]. The effect of erythro-
poietin on LV remodelling in acute MI has recently become
a topic of extensive research. The results of the HEBE III study
presented at the 2010 ESC Congress have not confirmed any
beneficial effect of erythropoietin on cardiac function in acu-
te MI [25].
CONCLUSIONS
1. The presence of anaemia, even mild anaemia, adversely
affected the outcomes. It was manifested by a poorer
haemodynamic status and was associated with a higher
risk of death and CV complications during the in-hospi-
tal period.
2. The adverse impact of anaemia on prognosis in patients
with STEMI undergoing PCI is complex and cannot be
solely explained by the mechanism of increased post-
infarction myocardial injury.
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S t r e s z c z e n i e
Wstęp: Wpływ współistniejącej niedokrwistości na występowanie i przebieg ostrych zespołów wieńcowych jest od niedawna
intensywnie badany. Dane na temat znaczenia niedokrwistości u pacjentów z zawałem serca z uniesieniem odcinka ST
(STEMI) leczonych interwencyjnie są mniej liczne, a wnioski niejednoznaczne.
Cel: Celem pracy była ocena częstości występowania i wpływu niedokrwistości na wczesne rokowanie u chorych leczonych
interwencyjnie z powodu STEMI.
Metody: Na podstawie retrospektywnej analizy dokumentacji hospitalizowanych chorych wyselekcjonowano grupę badaną,
którą stanowiło 551 kolejnych osób ze STEMI, w tym 164 kobiety (śr. wieku 63,4 ± 12 lat), poddanych pierwotnej interwen-
cji wieńcowej (PCI) w ciągu 12 godzin od początku bólu zawałowego. Niedokrwistość oceniano na podstawie morfologii
krwi przy przyjęciu wg definicji Światowej Organizacji Zdrowia (< 12 g/dL u kobiet i < 13 g/dL u mężczyzn).
Wyniki: U 61 (11%) badanych stwierdzono niedokrwistość (13% u kobiet, 10% u mężczyzn). Pacjenci z niedokrwistością byli
starsi (71 v. 63 lat; p < 0,001), mieli niższą masę ciała (70 v. 80 kg; p < 0,003), byli bardziej obciążeni wg skali ryzyka TIMI
dla STEMI (5 v. 3; p < 0,0001). W badaniach laboratoryjnych stwierdzono u nich bardziej upośledzoną funkcję nerek (GFR
66,8 v. 75,8 ml/min; p < 0,008) i wyższe stężenie białka C-reaktywnego (24,8 v. 14,4 mg/l; p< 0,001). Nie zaobserwowano
istotnej różnicy w stopniu pozawałowego uszkodzenia serca ocenianego na podstawie frakcji wyrzutowej oraz aktywności
wyjściowego i maksymalnego CK-MB. W trakcie leczenia w obu grupach zanotowano istotny spadek stężenia hemoglobiny
— z 11,9 do 11 g/dl u pacjentów z niedokrwistością (p < 0,0004) oraz z 14,3 do 13,3 g/dl u pozostałych osób (p < 0,001).
Wartość GFR nie zmieniała się istotnie u chorych z niedokrwistością, podczas gdy u pozostałych znamiennie wzrosła —
z 75,8 do 80,9 ml/min (p < 0,001). Śmiertelność wewnątrzszpitalna była niska, zmarło 8 (1,3%) chorych, 5 (8,2%)
wśród pacjentów z niedokrwistością i 3 (0,6%) spośród pozostałych osób. Różnica ta była bardzo znamienna statystycznie
(p < 0,001). W grupie z niedokrwistością częściej występowały również powikłania sercowo-naczyniowe (33% v. 17%;
p = 0,003). W analizie wieloczynnikowej starszy wiek, skurczowe ciśnienie tętnicze przy przyjęciu i leukocytoza wiązały się
ze zwiększonym ryzykiem zgonu oraz powikłań sercowo-naczyniowych, podczas gdy wyjściowe stężenie hemoglobiny było
istotnym statystycznie parametrem tylko w analizie jednoczynnikowej.
Wnioski: Chorzy z niedokrwistością, u których dochodzi do STEMI, stanowią od chwili przyjęcia do szpitala odrębną, bar-
dziej obciążoną populację, z wyraźnie większym ryzykiem zgonów i wewnątrzszpitalnych powikłań kardiologicznych. Nie-
korzystny wpływ niedokrwistości na rokowanie u chorych z ostrym zawałem serca leczonych inwazyjnie ma charakter złożo-
ny i nie może być wyjaśniony jedynie poprzez mechanizm większego zawałowego uszkodzenia serca. U chorych ze STEMI
niedokrwistość przy przyjęciu powinna być traktowana jako dodatkowy czynnik ryzyka.
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